Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Glargine in Type 2 Diabetes
NCT00563225Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2002
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label, single-arm trial of insulin glargine in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Primary endpoint: Hemoglobin A1c. Started Oct 2002; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00563225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00563225.